Northern Trust’s Stemline Therapeutics, Inc. STML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-635,591
| Closed | -$3.08M | – | 4338 |
|
|
2020
Q1 | $3.08M | Sell |
635,591
-1,498
| -0.2% | -$9.71K | ﹤0.01% | 2595 |
|
|
2019
Q4 | $6.77M | Buy |
637,089
+5,419
| +0.9% | +$53.8K | ﹤0.01% | 2409 |
|
|
2019
Q3 | $6.58M | Buy |
631,670
+108,329
| +21% | +$1.42M | ﹤0.01% | 2392 |
|
|
2019
Q2 | $8.02M | Buy |
523,341
+9,112
| +2% | +$132K | ﹤0.01% | 2288 |
|
|
2019
Q1 | $6.61M | Buy |
514,229
+119,727
| +30% | +$1.35M | ﹤0.01% | 2387 |
|
|
2018
Q4 | $3.75M | Sell |
394,502
-3,346
| -0.8% | -$43.4K | ﹤0.01% | 2675 |
|
|
2018
Q3 | $6.61M | Buy |
397,848
+17,470
| +5% | +$280K | ﹤0.01% | 2523 |
|
|
2018
Q2 | $6.11M | Buy |
380,378
+42,262
| +12% | +$754K | ﹤0.01% | 2581 |
|
|
2018
Q1 | $5.17M | Buy |
338,116
+42,537
| +14% | +$663K | ﹤0.01% | 2564 |
|
|
2017
Q4 | $4.61M | Buy |
295,579
+9,432
| +3% | +$126K | ﹤0.01% | 2663 |
|
|
2017
Q3 | $3.18M | Buy |
286,147
+11,323
| +4% | +$106K | ﹤0.01% | 2902 |
|
|
2017
Q2 | $2.53M | Buy |
274,824
+41,898
| +18% | +$349K | ﹤0.01% | 3027 |
|
|
2017
Q1 | $1.99M | Buy |
232,926
+29,095
| +14% | +$265K | ﹤0.01% | 3086 |
|
|
2016
Q4 | $2.18M | Buy |
203,831
+16,438
| +9% | +$199K | ﹤0.01% | 3040 |
|
|
2016
Q3 | $2.03M | Buy |
187,393
+7,280
| +4% | +$59.2K | ﹤0.01% | 3062 |
|
|
2016
Q2 | $1.22M | Buy |
180,113
+11,175
| +7% | +$70.5K | ﹤0.01% | 3284 |
|
|
2016
Q1 | $787K | Sell |
168,938
-264
| -0.2% | -$1.29K | ﹤0.01% | 3329 |
|
|
2015
Q4 | $1.07M | Sell |
169,202
-189
| -0.1% | -$1.53K | ﹤0.01% | 3300 |
|
|
2015
Q3 | $1.5M | Buy |
169,391
+9,673
| +6% | +$101K | ﹤0.01% | 3180 |
|
|
2015
Q2 | $1.88M | Buy |
159,718
+16,576
| +12% | +$230K | ﹤0.01% | 3093 |
|
|
2015
Q1 | $2.07M | Buy |
143,142
+21,828
| +18% | +$334K | ﹤0.01% | 3098 |
|
|
2014
Q4 | $2.07M | Sell |
121,314
-1,203
| -1% | -$17.4K | ﹤0.01% | 3081 |
|
|
2014
Q3 | $1.53M | Buy |
122,517
+13,571
| +12% | +$167K | ﹤0.01% | 3256 |
|
|
2014
Q2 | $1.6M | Sell |
108,946
-13,217
| -11% | -$203K | ﹤0.01% | 3199 |
|
|
2014
Q1 | $2.49M | Sell |
122,163
-11,521
| -9% | -$280K | ﹤0.01% | 3004 |
|
|
2013
Q4 | $2.62M | Buy |
133,684
+12,633
| +10% | +$337K | ﹤0.01% | 2991 |
|
|
2013
Q3 | $5.48M | Buy |
121,051
+79,194
| +189% | +$2.58M | ﹤0.01% | 2437 |
|
|
2013
Q2 | $998K | Buy |
+41,857
| New | +$667K | ﹤0.01% | 3270 |
|
Northern Trust's STML Position: Q2 2020 in Review
Northern Trust sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 635,591 shares — an estimated $3.08M sold.
Northern Trust first reported a position in STML in Q2 2013 and held it in 28 quarters. The position peaked at $8.02M in Q2 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.
- Northern Trust reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
- Northern Trust sold 635,591 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $3.08M.
- Northern Trust first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 28 quarters.
- Northern Trust's Stemline Therapeutics, Inc. position peaked at $8.02M in Q2 2019.
- 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.
Based on Northern Trust's 13F filing for Q2 2020, filed 14 Aug 2020.